Year Founded
2018
Ownership
Private
Employees
~50
Stage
Phase 3
Modalities
Small molecule

Emalex Biosciences General Information

Lead candidate ecopipam met primary and secondary endpoints in Phase 3 Tourette Syndrome study, showing statistical significance vs placebo in pediatric subjects (p=0.0084) and combined pediatric/adult subjects (p=0.0050)

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Chicago, Illinois
United States

Drug Pipeline

ecopipam
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Emalex Biosciences's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Emalex Biosciences Funding

Deal TypeDateAmountStatusStage
Later Stage VCNov 3, 2022$250.0MCompletedPhase 3
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Emalex Biosciences's complete valuation and funding history, request access »

Emalex Biosciences Investors

Paragon Biosciences
Investor Type: Venture Capital
Holding: Minority
Series D round raised $250 million from undisclosed investors in November 2022
Investor Type: Venture Capital
Holding: Minority